30.10.2015 • News

Evonik Starts Expanded Silica Plant in Japan

Evonik has started up its newly expanded production facilities for specialty silicas at Ako, Japan. The investment will increase by half capacity at the site of DSL, the German chemical producer’s joint venture with Shionogi.

The plant produces specialty silicas under the brand names Sipernat and Carplex, products used in top-end food, cosmetics, and pharmaceuticals applications such as beer filtration, drug carriers in pharmaceuticals and flow aids in powdered foods and thickener for toothpastes.

DSL President Tadashi Kanai said the new lines will strategically enhance the company’s already strong market position.

One of the largest global manufacturers of silicas, Evonik is expanding output in major markets. Following expansion in Europe and Asia, it is now focusing on Brazil, where a new facility at Americana, Brazil is being billed as the first plant in South America for highly dispersible (HD) silica, a product used primarily in tires with low rolling resistance.

Earlier this year, the German group began initial planning of a new world-scale plant for precipitated silica in the US, penciled in for completion by the end of 2017. The project, which would be its largest investment in North America in the past five years, is still subject to board approval.

Evonik puts its worldwide production capacity for matting agents and for precipitated and fumed silicas at roughly 550,000 t/y.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read